"Designing Growth Strategies is in our DNA"
The global hemorrhoid treatment market size was valued at USD 1.03 billion in 2023. The market is projected to grow from USD 1.08 billion in 2024 to USD 1.74 billion by 2032, exhibiting a CAGR of 6.1% during the forecast period.
Hemorrhoid is a condition in which the veins of the rectum and anus get swollen and inflamed, causing discomfort and bleeding. Hemorrhoids are a very common condition that affects millions of people worldwide and can be caused by factors such as straining during bowel movements, prolonged sitting, obesity, pregnancy, and chronic constipation. They are of two types: internal and external. The internal hemorrhoids, which lie inside the rectum, are usually painless but may cause bleeding during bowel movements. External hemorrhoids are located under the skin around the anus and can cause pain, discomfort, swelling, and itching. As the prevalence of hemorrhoids increases and the associated pain and discomfort rise, there is a greater adoption of hemorrhoid treatment products.
Additionally, the presence of key players in the market such as Church & Dwight Co., Inc., Haleon Group of Companies, Sebela Pharmaceuticals, and others with advanced product offerings for the treatment of hemorrhoids over-the-counter (OTC) and prescription boosts the adoption of the products and bolsters the market’s growth.
Rising Prevalence of Hemorrhoids to Propel Market Growth
The increasing prevalence of hemorrhoids is one of the most prominent drivers of the market. Hemorrhoids are a common gastrointestinal condition that occurs when there is extra pressure on the anus and lower rectum veins.
The increase in the prevalence of the disease among the geriatric population, coupled with poor hygiene and sanitary conditions in lower economic countries will drive the demand for more cost-effective treatment options to control and manage associated symptoms.
Growing Access to Over-the-Counter (OTC) Drugs for Hemorrhoids Treatment to Boost Market Growth
The rising availability of OTC drugs for the treatment of hemorrhoids is responsible for driving the hemorrhoid disease treatment market growth. The formulations used for the disease treatment are easily available without prescription and are convenient to the patients. Hemorrhoid drugs are widely available at drugstores and online pharmacies. Moreover, the strategic initiatives by key players to expand product reach are further propelling global hemorrhoid treatment market growth.
Social Stigma and Barriers to Seeking Medical Care to Restrict Market Growth
One of the key factors impeding market growth is the social stigma and barrier to seeking medical care for hemorrhoid treatment. Hemorrhoids are associated with bowel movements and can be a taboo topic, leading to embarrassment and reluctance to discuss and seek treatment.
Thus, social stigma and lack of reimbursement options are expected to continue impacting market growth during the forecast period. However, counseling and increasing awareness among the population may facilitate the stigma associated with hemorrhoids and encourage more people to seek treatments.
Availability of Alternative Treatments:
The presence of alternative treatment options for hemorrhoids is challenging the growth of the market. These alternatives include conservative methods such as softening the stool, pain relievers, and improving bad toileting habits. Office-based methods such as rubber band ligation, infrared coagulation, and sclerotherapy are cost-effective and reduce the recurrence rate of hemorrhoids. Thus, such scenarios shift the focus of patients toward these options and may hamper market growth.
Regulatory Hurdles and Approval Processes:
Currently, hemorrhoid disease has no FDA-approved drugs as companies across the globe need to clear strict regulatory hurdles for the approval of drugs. This process delays the commercialization of new treatments, further limiting market growth during the forecast period.
Potential Challenges and Obstacles:
Despite positive trends, the market may face several challenges, including social stigma, embarrassment, and also stringent regulations for pharmaceuticals could delay the introduction of new treatments and hinder innovation.
Insurance Coverage and Reimbursement Policies:
Lack of insurance coverage and reimbursement policies for the drug treatment of hemorrhoids is hampering the growth of the market in lower economic countries.
Gradual Increase in the Number of Pipeline Candidates for Hemorrhoid Treatment
One of the prevailing trends witnessed in the global market is the rising focus on research and development activities to fulfill the demand for targeted treatments addressing the core symptoms of hemorrhoids. Current treatment options often lack the therapeutic efficiency needed to target the core symptoms of hemorrhoid disease.
Clinical Trials and Their Outcomes:
Technological Advancements in Hemorrhoid Treatment:
The increasing demand for convenient formulations that offer faster drug delivery and rapid relief from hemorrhoid discomfort is prompting companies to focus on launching new products for patient comfort in the market. For example, the Haleon group of companies launched Preparation H Totables wipes, designed to numb the affected area, reducing inflammation, itching, and swelling.
Request a Free sample to learn more about this report.
The COVID-19 pandemic positively impacted the hemorrhoid treatment market. The positive impact on the market was due to the rise in the number of hemorrhoid patients during the pandemic, driven by a more sedentary lifestyle. Additionally, over-the-counter drugs for hemorrhoid treatment became more accessible, leading to higher sales and revenue generation. However, the market is expected to grow during the forecast period due to rising demand for adequate treatment options and product launches.
Cost Analysis of Hemorrhoid Treatments:
The management of hemorrhoids comprises conservative treatments such as topical medications and dietary changes to more advanced interventions, including rubber band ligation, sclerotherapy, and surgical procedures.
Economic burden of Untreated Hemorrhoids:
The economic burden of untreated hemorrhoids can be substantial. Untreated patients are more likely to experience severe pain, rectal bleeding, and complications such as thrombosis, resulting in emergency visits and hospitalizations. These incidents result in direct medical costs and contribute to indirect costs such as lost productivity.
Market Opportunities for Cost-Effective Treatments:
Emphasis on telemedicine and at-home treatment options can potentially increase the demand for over-the-counter products that enhance patient adherence to treatment regimens.
The regulatory landscape for the market is primarily governed by regulatory bodies such as the FDA in the U.S. and the EMA in Europe. These agencies oversee the approval processes for new treatments, ensuring their safety and efficacy. Manufacturers must comply with stringent manufacturing and labeling requirements, including clinical trial regulations. These regulations significantly impact market entry, often creating barriers that can limit competition and influence pricing strategies within the sector.
Ease of Application and Higher Adoption of the Creams & Ointments Propelled the Growth of the Creams & Ointments Segment
Based on product type, the market is divided into suppositories, sprays, creams & ointments, and others.
The creams & ointments segment held the lion’s share of the global hemorrhoids treatment market in 2023. The increasing prevalence of the disease across the globe and patients' preference for the use of creams & ointments due to ease of application, non-invasive symptom relief, and easy availability leads to the boosting growth of the segment. Additionally, increasing awareness programs about hemorrhoids are expected to further increase the adoption of these products for treating hemorrhoid symptoms.
The suppository segment held the second-largest global hemorrhoid treatment market share in 2023. The growth of the segment is augmented by the increasing number of cases associated with internal hemorrhoids and suppositories being preferred for grade I and II hemorrhoid patients for immediate and long-term relief. These factors are propelling the growth of the segment in the market.
Furthermore, the sprays and others segment is expected to grow modestly during the forecast period. Increasing demand for supplementary products for relieving constipation and rising demand for easy and convenient products for rectal application is expected to propel the segment’s growth during 2024-2032.
To know how our report can help streamline your business, Speak to Analyst
Corticosteroids Segment Dominated due to Wide Availability and Benefits Associated with Corticosteroids
Based on drug class, the market is divided into corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), local anesthetics, and others.
The corticosteroids segment held the dominant share of the market in 2023. Corticosteroids such as hydrocortisone are available in various formulations such as cream, ointment, and suppositories. These corticosteroids work by activating natural substances in the skin to reduce swelling, redness, and itching. These benefits promote the adoption of corticosteroids treatments, boosting the growth of the segment.
Additionally, the local anesthetics segment held the second-largest share of the market. Local anesthetics such as lidocaine and pramoxine are used to relieve pain and itching temporarily caused due to hemorrhoids. Key players in the market are offering different formulations of these treatments and raising awareness regarding hemorrhoids in the region.
The NSAIDs and others segment are expected to grow during the forecast period. The growth of the segment is augmented by the increasing demand for stool softeners, antibiotics, and pain-relieving medication for decreasing the symptoms associated with hemorrhoids. These factors are likely to promote the growth of the segment.
Internal Segment Dominated owing to Rising Prevalence of Internal Hemorrhoids
Based on type, the market is segmented into internal and external.
The internal segment held a significant share of the market. The internal hemorrhoids are further divided into grades I, II, III, and IV. The rising prevalence of internal hemorrhoids augments the growth of the segment. Additionally, increasing product demand for internal hemorrhoids is expected to propel the growth of the segment in the market.
Additionally, the external segment is expected to grow during the forecast period; rising prevalence and increasing product availability for external hemorrhoids are expected to propel the growth of the segment in the market.
Robust Availability of Over-the-counter Products for Hemorrhoids Treatment to Propel the Growth of the Drug Stores & Retail Pharmacy Segment
Based on distribution channel, the market is segmented into drug stores & retail pharmacies, online pharmacies, and hospital pharmacy.
The drugstore and retail pharmacy held a dominant share of the market. The dominant share of the segment is augmented by the wide range of product availability for hemorrhoid over-the-counter (OTC) and increasing patients' preferences for treating hemorrhoids by themselves due to social stigma. Additionally, increasing OTC product launches by key players to propel the segment’s growth.
Hospital pharmacies held the second-largest share of the segment in the market. The shift of patients toward hospitals after initial treatment with OTC products is attributed to the growth of the segment. Hospital pharmacies play a crucial role in meeting the demand for hemorrhoid treatment drugs as many medications for the treatment require a prescription following a thorough examination by trained medical professionals at these institutions.
The online pharmacies segment is expected to grow at the highest CAGR during the forecast period due to the increased adoption of digital pharmaceutical platforms. These platforms offer privacy for sensitive purchases, such as hemorrhoid treatments, and often integrate with telemedicine services. This enables patients to consult with healthcare professionals and obtain prescriptions online further fueling the growth of the global market.
The global market is divided into regions, including North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
North America Hemorrhoid Treatment Market Size, 2023 (USD Billion)
To get more information on the regional analysis of this market, Request a Free sample
The North America region dominated the hemorrhoid treatment market and was valued at USD 0.46 billion in 2023. In the North America region, U.S. dominated the region’s market. The presence of advanced healthcare facilities and government awareness programs leading towards the country’s growth in the market. Additionally, the overall region’s growth is due to the rising prevalence of hemorrhoids, the presence of advanced healthcare infrastructure, and key players in the market offering advanced product options.
Additionally, increasing research and development activities by key players to launch advanced treatments are likely to propel the market growth.
Europe held the second-largest position due to the rising prevalence of hemorrhoids and the strong regulatory environment with the presence of key players with advanced treatment options for hemorrhoids in the region.
Asia Pacific is expected to grow during the forecast period. The growth of the region is due to the rising patient population and rising awareness programs aimed at reducing the social stigma surrounding hemorrhoids and encouraging people to seek treatment.
Despite these efforts, social stigma remains a challenge in the region. However, the region’s rising population and presence of advanced healthcare facilities offer lucrative growth opportunities.
The Middle East & Africa are expected to grow during the forecast period. The growth of the region will be primarily due to the increasing prevalence of hemorrhoids, expansion of healthcare infrastructure, and easy availability of products with convenient applications. Thus, such scenarios are expected to propel the adoption of creams and ointments in the region.
Latin America is expected to grow during the forecast period due to the increasing prevalence of hemorrhoids, which is prompting key players to focus on expanding their footprints in the region.
Key Players Focus on Expanding their Product Offerings to Bolster their Market Position
In 2023, the Haleon Group of Companies is a major player in the market, with a robust product portfolio, strong geographical presence, and strategic activities aimed at expanding its offerings. Other key players in the market include Church & Dwight Co., Inc., AMATO PHARMACEUTICAL PRODUCTS, LTD., Sebela Pharmaceuticals, Bayer AG, Abbott, and Lupin. These companies offer a wide range of product offerings, including various OTC and prescription medications for hemorrhoids treatment, further strengthening their market position across the globe. Strategic initiatives, such as partnerships also contribute to the market growth.
For instance, in February 2024, Church & Dwight Co., Inc. renewed its partnership with DKSH Hong Kong to expand the reach of its Church & Dwight’s Anusol product range in Hong Kong through DKSH agency services.
Predicted Market Trends and Growth Areas:
The hemorrhoid treatment market is anticipated to experience significant growth over the coming years, driven by factors such as an increasing prevalence of hemorrhoids, heightened awareness regarding preventive healthcare, and advancements in medical technology. The demand for home remedies and over-the-counter treatments will likely rise due to preferred self-management options. Additionally, the integration of telemedicine for consultations and digital platforms for patient education and support will also shape the future landscape, improving accessibility for patients.
Opportunities for Innovation and Investment:
There are numerous opportunities for innovation and investment in the market, including investment in research to develop new, effective pharmacological solutions that can cater to a growing market segment seeking natural alternatives.
Additionally, the integration of technology can improve patient management and offer personalized treatment plans.
Recommendations for Stakeholders
To capitalize on the predicted growth in the market, stakeholders-including manufacturers, healthcare providers, and investors should focus on developing patient-centric solutions that prioritize comfort, convenience, and accessibility. This includes creating personalized at-home care kits and telehealth services.
The global report offers both qualitative and quantitative analysis of the global market, including a comprehensive examination of market size and growth rates across various segments. Additionally, the report includes market dynamics and the competitive landscape, providing key insights such as disease prevalence in different regions, industry advancements, pipeline analysis, regional analysis, alternative treatment methods for hemorrhoids, and the influence of COVID-19 on the market.
To gain extensive insights into the market, Request for Customization
ATTRIBUTE | DETAILS |
Study Period | 2019-2032 |
Base Year | 2023 |
Estimated Year | 2024 |
Forecast Period | 2024-2032 |
Historical Period | 2019-2022 |
Growth Rate | CAGR of 6.1% from 2024 to 2032 |
Unit | Value (USD billion) |
Segmentation | By Product Type
|
By Drug Class
| |
By Type
| |
By Distribution Channel
| |
By Region
|
Fortune Business Insights says that the global market size was USD 1.03 billion in 2023 and is projected to reach USD 1.74 billion by 2032.
In 2023, the North America market stood at USD 0.46 billion.
The market will grow at a CAGR of 6.1% in the forecast period (2024-2032).
The creams & ointments segment led the market.
The growing prevalence of hemorrhoids and growing access to over-the-counter (OTC) drugs for hemorrhoid treatment are key factors driving the global market.
Haleon Group of Companies, Church & Dwight Co., Inc., and Bayer AG are the leading global market players.
North America region dominated the market in 2023.
Related Reports
US +1 833 909 2966 ( Toll Free )